Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results

• Hansa secures the money inventory model round 232 Msek/US 24.3 million {dollars} And restructuring the money owed of Novaquest.

• In comparison with the earlier yr, IDEFirix merchandise elevated by 76 %.

Lund, Swedenand July 17, 2025 / PRNEWSWIRE/- Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), immediately introduced its non permanent report for the month of January- immediatelyJune 2025.

René Agoyiar Lukander, CEO, Hansa very important He stated, “Within the second quarter of 2025, the corporate succeeded in acquiring further financing and restructuring the present debt settlement with Novaquest, guaranteeing the flexibility to report information on two principal section packages in kidney transplantation, and fight GBM traces. Europe“

Monetary efficiency

In Q2 2025, Hansa has accomplished a rise in profitable capital with the assist of recent and present shareholders. Funding will assist experimental readings from the third stage within the second half of 2025, together with the central expertise of kidney transplantation and the Good-IDD-02 expertise in GBM management.

As a part of a guided arrow case, Hansa and Novaquest entered right into a modified debt settlement through which the corporate compensates us 14.9 million {dollars} From the suspended money owed by issuing new shares (property rights). The remaining money owed might be paid in mounted money funds in June 2027and June 2028 and June 2029. As well as, there may be virtually actual fee to us 14.9 million {dollars} due to January 31, 2026Which will be settled in money or property rights in keeping with the corporate’s estimate.

IDEFirX Q2 merchandise elevated by 76 % in comparison with the identical interval final yr. In Q2 2025, the corporate offered 47.8 Msek in IDEFirix gross sales that replicate a rise of 76 % in comparison with the earlier yr (27.2 Msek) in the identical time interval. For 1H 2025, IDEFirix 113.5 MSEK gross sales represented a 52 % improve in product gross sales over 1 hour 2024, which represents about 80 % of merchandise gross sales for a full yr for 2024.

The pipeline is obtainable

The corporate remains to be heading in the right direction to report information from a 20-Hedaydy-17 (belief) examine. It’s anticipated to submit a organic license request (BLA) to the US Meals and Drug Administration (FDA) within the second half 2025, after studying the information.

Constructive information was offered by the 15-Hesse-09 experiment within the second stage, together with evaluating oblique therapy, with the examine of the outcomes of the worldwide Guillain-Barré syndrome (IGOS) on the annual assembly of the ocean nerve affiliation (PNS) in Could.

Registration continues in GNT-018-Mide, Stage 2 Expertise in Crigler carpenter To evaluate the effectiveness and integrity of the genetic remedy of the GNT-0003 after pre-processing with IMLIFIDASE. Stage 1b SRP-9001-104 with Sarepta stays on the suitable path to learn uncooked information later this yr.